There are 2185 resources available
852MO - REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Presenter: Joël Castelli
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
1253O - Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
Presenter: Alexander Drilon
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
853MO - Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
Presenter: Jérome Fayette
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
854MO - Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial
Presenter: Yungan Tao
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
373P - Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study
Presenter: Norikazu Masuda
Session: Poster session 15
Resources:
Abstract
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
Resources:
Abstract
374P - Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
Presenter: Mario Campone
Session: Poster session 15
Resources:
Abstract
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
Resources:
Abstract
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
Resources:
Abstract
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
Resources:
Abstract